VECURONIUM BROMIDE VIALS

Initial- For intubation- Intravenous, 80 to 100 mcg (0.08 to 0.1 mg) per kg of body weight . For administration after the patient has been anesthetized with enflurane or isoflurane (i.e., more than 5 minutes after anesthesia has been instituted or after steady state has been achieved)- Intravenous, 60 to 85 mcg (0.06 to 0.085 mg) per kg of body weight, or approximately 15% less than the usual initial dose . For administration after succinylcholine-assisted endotracheal intubation - Intravenous, 40 to 60 mcg (0.04 to 0.06 mg) per kg of body weight under inhalation anesthesia, or 50 to 60 mcg (0.05 to 0.06 mg) per kg of body weight under balanced anesthesia . The effects of succinylcholine, as determined with a peripheral nerve stimulator, should be permitted to subside prior to administration of vecuronium . Note: If larger initial doses are required by the individual patient, initial doses ranging from 150 to 280 mcg (0.15 to 0.28 mg) per kg of body weight have been administered during surgery with halothane anesthesia without adverse effects on the cardiovascular system occurring, provided that adequate ventilation was maintained . Supplemental- Intravenous, 10 to 15 mcg (0.01 to 0.015 mg) per kg of body weight, administered twenty-five to forty minutes following the initial dose, then every twelve to fifteen minutes or as required by clinical conditions ; or Intravenous infusion (initiated after recovery from the effects of an initial intravenous dose of 80 to 100 mcg per kg of body weight has begun): 1 mcg (0.001 mg) per kg of body weight per minute, initially, then adjusted according to clinical requirements and patient response . Average infusion rates may range from 0.8 to 1.2 mcg (0.0008 to 0.0012 mg) per kg of body weight per minute . After steady-state enflurane or isoflurane anesthesia has been established - The required rate of infusion may be reduced by 25 to 60%. This reduction may not be required for patients anesthetized with halothane .

MAXIMUM ADULT DOSE:

PEDIATRIC DOSE:

Neonates- Dosage has not been established. Patients 7 weeks to 1 year of age- Dosage must be individualized. Pediatric patients 7 weeks to 1 year of age are more sensitive to the effects of vecuronium than adults and recovery time may be 11/2 times that of adults . Patients 1 to 10 years of age- Dosage must be individualized. Pediatric patients 1 to 10 years of age may require a slightly higher initial dose and slightly more frequent supplemental doses than adults . Patients 10 years of age and older- Initial- See Usual adult and adolescent dose . Supplemental- Intravenous-See Usual adult and adolescent dose. Intravenous infusion-Dosage has not been established .

MAXIMUM PEDIATRIC DOSE:

ELDERLY DOSE:

PREVIOUS

NEXT